CONFERENCE POSTER
Study of the Initial Response to Lopinavir/ritonavir in HIV Treatment
Experienced Patients: The ATU Pre-Registration Cohort in France.
P. NgoVan, et al.
PDF Poster

CONFERENCE POSTER
Lopinavir/ritonavir Pre-Registrational Usage in France (ATU): A 2000 to 2001
Insight into theTherapeutic Trends and Outcome in HIV Treatment Patients.
Cohen Codar, et al.
PDF Poster

CONFERENCE POSTER
Efficacy of Lopinavir/ritonavir in Multiple PI-Experienced Patients According
to Mutational Patterns: Data from the French ATU Program.
V. Calvez, et al.
PDF Poster

CONFERENCE POSTER
Collection of Drug Adverse Events in Pre-Registration Access Programs:
What Relevance Compared to Controlled Studies? Analysis of the
French ATU Cohort for Kaletra.
E.Boer et al.
PDF Poster

CONFERENCE POSTER
Results from the Kaletra Early Access Program in Canada.
J. Montaner and the Canadian EAP Study Group
PDF Poster

CONFERENCE POSTER
Efficacy and Safety Results from the LPV/r Early Access Program in
Germany.
JK Rockstroh, et al.
PDF Poster

CONFERENCE POSTER
Initial Efficacy and Safety Results from the Lopinavir/ritonavir (LPV/r,
 Kaletra) Early Access Program in Italy.
A Germinario, et al
PDF Poster

CONFERENCE POSTER
Efficacy amd Safety Results of Lopinavir-Based HAART Treatment
in Expanded Access Program in Spain Through W24.
B. Clotet, et al.
PDF Poster

CONFERENCE POSTER
Kaletra (Lopinavir/ritonavir) Therapy in Single Protease Inhibitor Patients:
144-Week Follow-up.
C. Hicks, et al.
PDF Poster

CONFERENCE POSTER
Kaletra (lopinavir/ritonavir) in Antiretroviral-Naive HIV+ Patients: 3-Year Follow-Up.
M. Thompson, et al.
PDF Poster

CONFERENCE POSTER
Treatment of HIV+ Subjects Co-infected with Hepatitis B or C: Week 60
Safety and Efficacy  Comparison of LPV/r vs. Nelfinavir from a Phase III
Blinded Randomized Clinical Trial.
B. Bernstein, et al.
PDF Poster